FWA
CRSP icon

Flagship Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Flagship Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.73K Hold
200
– – ﹤0.01% 285
2025
Q4 		$10.5K Hold
200
– – ﹤0.01% 326
2025
Q3 		$13K Hold
200
– – ﹤0.01% 312
2025
Q2 		$9.73K Hold
200
– – ﹤0.01% 300
2025
Q1 		$6.81K Hold
200
– – ﹤0.01% 319
2024
Q4 		$7.87K Buy
+200
New +$9.44K ﹤0.01% 303

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Wealth Advisors's CRSP Position: Q1 2026 in Review

Flagship Wealth Advisors held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 200 shares worth $9.73K. The position accounts for ﹤0.01% of the portfolio, ranked #285.

Flagship Wealth Advisors first reported a position in CRSP in Q4 2024 and has held it in 6 quarters since. The position peaked at $13K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Flagship Wealth Advisors held 200 shares of CRISPR Therapeutics worth $9.73K as of Q1 2026.
  • Flagship Wealth Advisors left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Flagship Wealth Advisors's portfolio in Q1 2026, its #285 holding.
  • Flagship Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Flagship Wealth Advisors's CRISPR Therapeutics position peaked at $13K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Flagship Wealth Advisors's 13F filing for Q1 2026, filed 1 Jun 2026.